Cabozantinib is a multi-tyrosine kinase inhibitor primarily targeting tyrosine-protein kinase Met (c-MET), vascular endothelial growth factor receptor 2 (VEGFR2), and tyrosine kinase receptors AXL and RET, which was initially approved to treat medullary thyroid cancer or advanced renal cell carcinoma (RCC) (11, 12). Here, KDR is linked to medullary thyroid gland carcinoma.